Innate Net Interest Income from 2010 to 2026
| IPHA Stock | USD 1.78 0.04 2.30% |
Net Interest Income | First Reported 2010-12-31 | Previous Quarter 2.2 M | Current Value 2.3 M | Quarterly Volatility 1.2 M |
Check Innate Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Innate Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.2 M, Interest Expense of 683.4 K or Selling General Administrative of 13.7 M, as well as many indicators such as Price To Sales Ratio of 10.18, Dividend Yield of 0.0023 or PTB Ratio of 12.58. Innate financial statements analysis is a perfect complement when working with Innate Pharma Valuation or Volatility modules.
Innate | Net Interest Income | Build AI portfolio with Innate Stock |
Analyzing Innate Pharma's Net Interest Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Interest Income has evolved provides context for assessing Innate Pharma's current valuation and future prospects.
Latest Innate Pharma's Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Innate Pharma over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Innate Pharma's Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Innate Pharma's overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Innate Net Interest Income Regression Statistics
| Arithmetic Mean | 852,346 | |
| Geometric Mean | 928,626 | |
| Coefficient Of Variation | 138.28 | |
| Mean Deviation | 880,565 | |
| Median | 686,000 | |
| Standard Deviation | 1,178,600 | |
| Sample Variance | 1.4T | |
| Range | 4.4M | |
| R-Value | 0.37 | |
| Mean Square Error | 1.3T | |
| R-Squared | 0.14 | |
| Significance | 0.14 | |
| Slope | 87,459 | |
| Total Sum of Squares | 22.2T |
Innate Net Interest Income History
About Innate Pharma Financial Statements
Innate Pharma stakeholders use historical fundamental indicators, such as Innate Pharma's Net Interest Income, to determine how well the company is positioned to perform in the future. Although Innate Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Innate Pharma's assets and liabilities are reflected in the revenues and expenses on Innate Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Innate Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 2.2 M | 2.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out the analysis of Innate Pharma Correlation against competitors. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. Market participants price Innate higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Innate Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.75) | Earnings Share (0.65) | Revenue Per Share | Quarterly Revenue Growth (0.61) | Return On Assets |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Innate Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.